Search Results - "Fuchs, Candace A." :: K.UTB vyhledávací portál

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers

by Magid Diefenbach, Catherine S., Cohen, Jonathan B, Harb, Wael A., Ansell, Stephen M., Nastoupil, Loretta J., Abramson, Jeremy S., Lakhani, Nehal J., Schreeder, Marshall T., Sher, Taimur, Patel-Donnelly, Dipti, Aboulafia, David Michael, Fuchs, Candace A., Nix, Darrell, Landrette, Sean, Graham, Patricia S, King, Lydia B, Young, Peter L., Miller, Langdon L., Lichenstein, Henri, Rutherford, Sarah C.
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

Loading…

A new lectin in red kidney beans called PvFRIL stimulates proliferation of NIH 3T3 cells expressing the Flt3 receptor

by Moore, Jeffrey G., Fuchs, Candace A., Hata, Yujiro S., Hicklin, Daniel J., Colucci, Gabriella, Chrispeels, Maarten J., Feldman, Michael
Published in Biochimica et biophysica acta (26.07.2000)

Get full text

Journal Article

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers

A new lectin in red kidney beans called PvFRIL stimulates proliferation of NIH 3T3 cells expressing the Flt3 receptor

Refine Results

Format

Subject Area

Topic

Language

Year of Publication

Database